Atsushi Utsuno

A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term <scp>ASP1941</scp> Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

Atsunori Kashiwagi, Hideyuki Takahashi, Hiroshi Ishikawa et al. · Diabetes Obesity and Metabolism · 2014 · 115 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study

Atsunori Kashiwagi, Kenichi Kazuta, Yuusuke Takinami et al. · Diabetology International · 2014 · 83 citations

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study

Atsunori Kashiwagi, Noriko Akiyama, Takanori Shiga et al. · Diabetology International · 2014 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Atsunori Kashiwagi, Takanori Shiga, Noriko Akiyama et al. · Diabetology International · 2014 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +14

Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects

Takeshi Kadokura, Masako Saitō, Atsushi Utsuno et al. · Diabetology International · 2011 · 38 citations

Medicine, Endocrinology, Pharmacology +14